title: New adamantane derivatives with sigma affinity and antiproliferative activity.
abstract: The synthesis of 4-(1-adamantyl)-4,4-diarylbutylamines 1, 5-(1-adamantyl)-5,5-diarylpentylamines 2 and 6-(1-adamantyl)-6,6-diarylhexylamines 3 is described and the σ1, σ2-receptors and sodium channels binding affinity of compounds 1 were investigated. The in vitro activity of compounds 1, 2 and 3 against main cancer cell lines is significant. One of the most active analogs, 1a, had an interesting in vivo anticancer profile against the ovarian cancer cell line IGROV-1, which was associated with an anagelsic activity against the neuropathic pain induced by the main anticancer drugs.
authors.affiliation: Faculty of Pharmacy, Department of Pharmaceutical Chemistry, University of Athens, Panepistimioupoli-Zografou, 157 71 Athens, Greece.
authors.forename: Stefanos
authors.initials: S
authors.lastname: Riganas
authors.forename: Ioannis
authors.initials: I
authors.lastname: Papanastasiou
authors.forename: George B
authors.initials: GB
authors.lastname: Foscolos
authors.forename: Andrew
authors.initials: A
authors.lastname: Tsotinis
authors.forename: Kostas
authors.initials: K
authors.lastname: Dimas
authors.forename: Vassilios N
authors.initials: VN
authors.lastname: Kourafalos
authors.forename: Andreas
authors.initials: A
authors.lastname: Eleutheriades
authors.forename: Vassilios I
authors.initials: VI
authors.lastname: Moutsos
authors.forename: Humaira
authors.initials: H
authors.lastname: Khan
authors.forename: Prassa
authors.initials: P
authors.lastname: Margarita
authors.forename: Stavroula
authors.initials: S
authors.lastname: Georgakopoulou
authors.forename: Angeliki
authors.initials: A
authors.lastname: Zaniou
authors.forename: Maria
authors.initials: M
authors.lastname: Theodoropoulou
authors.forename: Athanasios
authors.initials: A
authors.lastname: Mantelas
authors.forename: Stavroula
authors.initials: S
authors.lastname: Pondiki
authors.forename: Alexandre
authors.initials: A
authors.lastname: Vamvakides
mesh_terms: D000218:Adamantane / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology* / Q000627:therapeutic use; D001665:Binding Sites; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D015195:Drug Design; D005260:Female; D006801:Humans; D008297:Male; D051379:Mice; D016513:Mice, SCID; D009369:Neoplasms / Q000188:drug therapy; D017480:Receptors, sigma / Q000737:chemistry*
chemical_list: D000970:Antineoplastic Agents; D017480:Receptors, sigma; D000218:Adamantane